Buscar
Mostrando ítems 1-10 de 27
Breast cancer stem cells are involved in Trastuzumab resistance through the HER2 modulation in 3D culture
(Wiley-liss, Div John Wiley & Sons Inc, 2018-02)
Breast cancer human cells culture as spheroids develop autophagy and apoptosis, which promotes Trastuzumab resistance in HER2 overexpressing cells. Our aim was to study the association of the hostile environment developed ...
Efectividad de Trastuzumab en combinación con terapia sistémica en pacientes con cáncer de mama avanzados o metastásico HER2 positivos. Experiencia del Hospital México, Costa Rica
(2017-08)
Introducción: Este estudio reporta la efectividad y seguridad del uso de trastuzumab en combinación con terapia sistémica en el tratamiento de pacientes con cáncer de mama localmente avanzado o metastásico, HER2 positivos. ...
TNFα-induced mucin 4 expression elicits trastuzumab resistance in HER2-Positive breast cancer
(American Association for Cancer Research, 2016-10-03)
Although trastuzumab administration improved the outcome of HER2-positive breast cancer patients, resistance events hamper its clinical benefits. We demonstrated that TNFα stimulation in vitro induces trastuzumab resistance ...
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
(MASSACHUSETTS MEDICAL SOCWALTHAM, 2012-01)
BACKGROUND The anti-human epidermal growth factor receptor 2 (HER2) humanized monoclonal antibody trastuzumab improves the outcome in patients with HER2-positive metastatic breast cancer. However, most cases of advanced ...
Erbb2+metastatic breast cancer treatment after progression on trastuzumab: a cost-effectiveness analysis for a developing country
(Revista de Salud Pública, 2014-05-01)
Objective Breast cancer (BC) and metastatic breast cancer (MBC) are significant causes of deaths amongst women worldwide, including developing countries. The cost of treatment in the latter is even more of an issue than ...
Recent treatment advances in HER2-positive metastatic breast cancer: a clinical approach
(2012-05)
The use of targeted therapy directed against HER2 is currently the standard of care in patients with metastatic HER2-positive breast cancer. The combination of trastuzumab with a taxane as first-line treatment in HER2-positive ...
Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer
(BioMed Central, 2017-12)
Invasive micropapillary carcinoma of the breast (IMPC) is a histological tumor variant that occurs with low frequency characterized by an inside-out formation of tumor clusters with a pseudopapillary arrangement. IMPC is ...
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
(ELSEVIER SCIENCE INC, 2011)
Background Treatment with adjuvant trastuzumab for 1 year improves disease-free survival and overall survival in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. We aimed to assess ...
Neuregulin-1/erbB activities with focus on the susceptibility of the heart to anthracyclines
(Baishideng Publishing Group, 2014-07)
Neuregulin-1 (NRG1) signaling through the tyrosine kinase receptors erbB2 and erbB4 is required for cardiac morphogenesis, and it plays an essential role in maintaining the myocardial architecture during adulthood. The ...